DNAprint Genomics (DNAG)

[SlopsterSlasher]

Special from Lonnie Bookbinder, PhD, MBA to RIBI shareholders at www.rsvc.org

The author of these observations has a thirty-year career in biopharmaceuticals and worked for RIBI from 1994-1997.

As most are aware, the majority of RIBI sales are derived from MPL and other adjuvants, which are refined as a part of a modified bacteria causing a cascading effect of immune responses. RIBI adjuvants, especially MPL, are considered valuable and useful in many different vaccine candidates.

Importantly, to expand the base of knowledge, RIBI scientists initiated research to develop a synthetic adjuvant and have been successful. They have discovered, synthesized, tested and patented a next generation of super adjuvants. Think of these discoveries as a valuable franchise for the future of immunology. RIBI publications note that RIBI's second generation adjuvant technology platform is based on novel AGP- aminoalkyl glucosamine phosphate- adjuvants. These new synthetic compounds display potent bioactivity, possess an excellent safety profile and are amenable to alternative methods for vaccine delivery, such as intranasal delivery. Synthetic AGP compounds also may prove advantageous in ease of formulation, manufacturing scale-up and simplified quality assurance. In the hands of RIBI scientists, AGP's have been successfully used in pre-clinical testing of tetanus, hepatitis and influenza vaccines. RIBI scientists and managers confirm the worth of the AGP product derivatives and vaccine producers want it. There is a very significant potential value in AGP for RIBI.

This writer believes that RIBI is a treasure trove of potential and actual lines of research and that RIBI stock is worth much more than $2.00 per share. This writer believes that the RIBI Shareholder Value Committee suggestions represent the best way to realize the longterm value of RIBI Shares. Defeat of the Corixa offer is the first step in the right direction. Eighteen years of RIBI employees' scientific research and development deserves to be fully exploited. A sell out merger at $2.00 per share should be unsatisfactory to independent RIBI shareholders.
see my post from - http://www.investorshub.com/boards/read_msg.asp?message_id=1252974